Baxter International Inc. stock falls 5.80% amid broad market downturn

9 articles · Updated · MarketWatch · Apr 29

Shares closed at $16.90 on Wednesday, marking a second consecutive day of losses and trading 48.29% below the 52-week high of $32.68.
Baxter underperformed competitors like Medtronic, Stryker, and Becton Dickinson, with trading volume surging to 15.3 million, well above the 50-day average of 8.9 million.
The decline occurred during a generally weak session for the S&P 500 and Dow Jones, reflecting broader market pressures affecting healthcare stocks.

With earnings tomorrow, can Baxter's new strategy reverse its massive stock drop?

Is Baxter's stock, now 48% off its high, a deep value trap or a prime turnaround opportunity?

How will ongoing FDA holds and legal probes impact Baxter's path to recovery?

As rivals embrace AI, is Baxter falling too far behind in the MedTech innovation race?

Will selling its Kidney Care unit truly solve Baxter's deep-rooted debt and performance issues?